Philip Mack, PhD

Adjunct Professor

  • 4800 Citations
  • 40 h-Index
1995 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Philip Mack is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 22 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2002 2021


DeGregorio, M., Matthews, D., Felton, J. S., deVere White, R. W., Radke, K., Lloyd, K. K., Gandara, D. R., Beckett, L. A., Gregg, J., Luciw, P. A., Kung, H., Gumerlock, P. H., Mack, P., Evans, C. P., Lara, P. N., Lam, K., Chen, X., Kelly, K., Cherry, S. R., Shacklett, B., Lloyd, K. C. K. & Chen, M.

National Institutes of Health


Project: Research project

Organized Financing
Research Personnel
Clinical Trials
Tumor Biomarkers
Lung Neoplasms
Plasminogen Activator Inhibitor 1

Research Output 1995 2019

2 Citations (Scopus)

Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

Duan, Z., Chinn, D., Tu, M. J., Zhang, Q. Y., Huynh, J., Chen, J., Mack, P., Yu, A. & Kim, E., Apr 1 2019, In : Translational Oncology. 12, 4, p. 683-692 10 p.

Research output: Contribution to journalArticle

Open Access
Pancreatic Neoplasms
Aurora Kinase A

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer

Heath, E., Heilbrun, L., Mannuel, H., Liu, G., Lara, P. N., Monk, J. P., Flaig, T., Zurita, A., Mack, P., Vaishampayan, U., Stella, P., Smith, D., Bolton, S., Hussain, A., Al-Janadi, A., Silbiger, D., Usman, M. & Ivy, S. P., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Multicenter Studies
Prostatic Neoplasms
Drug Therapy
3 Citations (Scopus)
Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases

Re: Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial

Messing, E. M., Tangen, C. M., Lerner, S. P., Sahasrabudhe, D. M., Koppie, T. M., Wood, D. P., Mack, P. C., Svatek, R. S., Evans, C. P., Hafez, K. S., Culkin, D. J., Brand, T. C., Karsh, L. I., Holzbeierlein, J. M., Wilson, S. S., Wu, G., Plets, M., Vogelzang, N. J. & Thompson, I. M., Mar 1 2019, In : Journal of Urology. 201, 3, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Intravesical Administration
Urinary Bladder Neoplasms
Randomized Controlled Trials
2 Citations (Scopus)

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Aggarwal, C., Redman, M. W., Lara, P. N., Borghaei, H., Hoffman, P., Bradley, J. D., Newman, A. J., Feldman, M. J., Minichiello, K., Miao, J., Mack, P. C., Papadimitrakopoulou, V. A., Herbst, R. S., Kelly, K. & Gandara, D. R., Jan 1 2019, In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Fibroblast Growth Factor Receptors
Squamous Cell Neoplasms
Fibroblast Growth Factors
Lung Neoplasms
Confidence Intervals